Obstructive sleep apnea (OSA) with associated excessive daytime sleepiness (EDS) negatively and diversly impacts millions of patients. With the goal of improving patient quality of life, health care professionals (HCPs) will explore the constellation of symptoms patients with OSA-associated EDS may experience and will consider real-world treatment strategies to personalize care and optimize outcomes—like in our patient, Donovan, who initiated continuous positive airway pressure (CPAP) treatment 3 months ago but continues to be “tired all the time” and experiences negative work consequences and personal safety concerns.
Join us for this second of three BriefCase activities in which our expert faculty interweaves foundational knowledge with exercises for HCPs to practice new learnings with a case that emulates a patient with OSA and EDS seen in clinical practice.
Evaluate the constellation of patient symptoms (e.g., EDS, cognitive impairment, functioning) that influence treatment selection for EDS associated with OSA.
Supported by an educational grant from Axsome.
Sleep specialists, neurologists, psychiatrists, pulmonologists, primary care practitioners, nurse practitioners (NPs), physician associates (PAs), and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Bogan reports the following financial relationships:
Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report::
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
BC-098-080423-84
